CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses

USA - English

• USA - español
• USA - čeština
• USA - Deutsch
• USA - Polski
• USA - slovenčina

New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl^® Technology^*1 to Slow the Worsening of Myopia in Children^†2,3

FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay^® MiSight^® 1 day contact lenses in the UK and select European and surrounding markets, expanding its evidence-based myopia management portfolio. This new myopia control soft contact lens combines the proven MiSight^® 1 day ActivControl^® Technology with the advanced silicone hydrogel material used in MyDay^® lenses.^*1

One in two children born today could have myopia by the age of 20.⁴ Also known as nearsightedness, myopia can significantly impact their quality of life—making it harder to participate in school, sports, and other activities.^5,6 Myopia can worsen rapidly, especially in younger children, so early intervention is important.⁷

"Our commitment to tackling myopia—both scientifically and commercially—has been unwavering," said Debbie Olive, Chief Commercial Officer for CooperVision. "With MyDay^® MiSight^® 1 day, we've applied the advanced silicone hydrogel material found in our MyDay^® contact lenses^*1 while harnessing the life-changing potential of myopia control."^†2,3,8 

The company's ActivControl^® Technology has demonstrated an approximate 50% reduction in myopia progression^†2,3 and is backed by the longest-running soft contact lens clinical trial among children.^§ Hundreds of thousands of children globally now wear contact lenses featuring this technology.⁹ The lens design incorporates vision correction zones and treatment zones to provide clear vision while helping to control the worsening of myopia.^◊10-12

"This innovation delivers 'always-on' myopia control—children benefit from treatment throughout the day, simply by wearing their contact lenses," said Jennifer Lambert, Vice President, Myopia Management and Cornea Care, CooperVision.^¶13-15 "It's also designed to help support a smooth transition from myopia management to adult lens wear, thanks to its shared material and specifications with MyDay^® lenses."^**

At launch in the UK and select European and surrounding markets, the product will be available in the following parameters:

To learn more about this innovation and CooperVision's evidence-based myopia management portfolio, visit www.coopervision.co.uk.

# # #

About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over 50 million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding the launch of MyDay^® MiSight^® 1 day. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact
Laura DiCaprio, APR
McDougall Communications for CooperVision
[email protected] or +1-585-434-2148

Footnotes

* Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period

† Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day

‡ Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period.

§ MyDay® MiSight® 1 day contact lenses use the same ActivControl® Technology as the original MiSight® 1 day

◊ MyDay® MiSight® 1 day contact lenses use the same ActivControl® Technology as the original MiSight® 1 day

¶ In clinical study, mean weekday wear time increased from 12.8 hours/day at 6-months to 13.9 hours/day at 6-years with a mean of >6.5 days/week for MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day

** MyDay® daily disposable and MyDay Energys®

References

1. Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567
2. Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333.
3. CVI data on file, 2025
4. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042
5. E. L. Lamoureux et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469.
6. Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia:53-63. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore
7. K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306.
8. Vision standards and requirements. Association of Optometrists. (n.d.). Retrieved December 20, 2021, from https://www.aop.org.uk/advice-and-support/clinical/vision-standards
9. CVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of October 2024 to September 2025
10. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. OVS 2019; 96(8):556-567. -
11. CVI data on file, 2025. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel. N=32 subjects aged 8-18 years. -
12. CVI data on file, 2025
13. Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391. -
14. CVI data on file, 2025. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel. N=32 subjects aged 8-18 years. -
15. CVI data on file, 2025

Logo - https://mma.prnewswire.com/media/2854596/CooperVision_Logo.jpg

Photo - https://mma.prnewswire.com/media/2854597/CooperVision_MyDay_MiSight_1Day_Contact_Lenses.jpg